MIM
CYTK icon

Monashee Investment Management’s Cytokinetics CYTK Stock Holding History

Monashee Investment Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-100,000
Closed -$6.59M – 30
2026
Q1 		$6.59M Buy
100,000
+25,000
+33% +$1.59M 3.59% 8
2025
Q4 		$4.77M Sell
75,000
-25,000
-25% -$1.56M 2.69% 15
2025
Q3 		$5.5M Buy
+100,000
New +$4.12M 2.74% 13
2022
Q3 		– Sell
-45,000
Closed -$1.77M – 58
2022
Q2 		$1.77M Buy
+45,000
New +$1.81M 0.64% 15

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Monashee Investment Management's CYTK Position: Q2 2026 in Review

Monashee Investment Management sold out of Cytokinetics (CYTK) in Q2 2026, closing a stake of 100,000 shares — an estimated $6.59M sold.

Monashee Investment Management first reported a position in CYTK in Q2 2022 and held it in 4 quarters. The position peaked at $6.59M in Q1 2026. 483 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Monashee Investment Management reported no remaining Cytokinetics position as of Q2 2026 after selling out during the quarter.
  • Monashee Investment Management sold 100,000 Cytokinetics shares in Q2 2026, an estimated $6.59M.
  • Monashee Investment Management first reported a position in Cytokinetics in Q2 2022 and held it in 4 quarters.
  • Monashee Investment Management's Cytokinetics position peaked at $6.59M in Q1 2026.
  • 483 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Monashee Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.